Summary m-L-sarcolysin (m-L-SL) is an isomer of melphalan (Mel) with the di(2-chloroethyl) amino group being substituted in the meta position of phenylalanine. By covalent conjugation of amino acids to m-L-SL. a peptide complex consisting of six m-L-SL-based oligopeptides known as peptichemio (PTC) was developed previously. In the present study, the cytotoxic activity pattem of the different oligopeptides of PTC was investigated in ten human tumour cell lines representing different mechanisms of cytotoxic drug resistance using the fluorometric microcufture cytotoxicity assay (FMCA). In the cell line panel, Keywords: melphalan: L-prolyl-m-L-sarcolysyl-L-p-fluorophenylalanine; cytotoxicity assay; human tumour cell: drug resistance m-L-sarcolx sin ( m-L-SL ) is an isomer of melphalan ( Mel) wxith the di( 2-chloroethv1) amino group being substituted in the meta position of phenx lalanine. Bv cox-alent conju2ation of different aniino acids at the amino and carboxxl groups of m-L-SL. a peptide complex including six oligopeptides knoxx-n as peptichemio (PTC) \vas svnthesized prexiouslx (De Barbieri. 1972 ). The main rationale for svnthesizing, PFC wias that of creatin2 a substance that is simultaneouslx endowed w-ith cxtotoxic actix-itv because of the alkx lating group and a selecti-xe uptake in neoplastic cells (De Barbieri. 1972 ). In sexeral clinical inxestigations. PTC has showin actix itx in a Aiide spectrum of human malignancies (Hug et al. 1980 : Paccagnella et al. 1985). In the clinic PTC has showin acti-it-in human multiple myeloma resistant to treatment wxith alkvlating agents IPaccagnella et al. : Zaniboni et al. 1988 . Increased cx-totoxicitx-exerted by PTC as compared w-ith Mel and m-L-SL has been showin on tumour cell lines (Lewxensohn et al. 1991a). One of the alkylating peptides in PTC is L-prolyl-m-Lsarcol\s -l-L-p-fluorophenx lalamnne (P21. We haxe previously found that P2 is sex-eral-fold more toxic to human melanoma cells than m-L-SL alone w-hen tested bv a clono2enic assav (Hansson et al. 19911. Increased levels of DNA cross-link-in2 w-ere noted after 
The 8'26/Dox, x was selected for doxorubicin resistance and shows the classical MDR phenotype with oxverexpression of Pglxcoprotein 170 (Dalton et al. 1986 ). The 82"6/LR-5 w-as selected for NMel resistance. proposed to be associated w-ith increased lexels of glutathione (Bellamr et al. 1991 : Mulcahv et al. 1994 ). The t-937-Vcr was selected for -incristine resistance. proposed to be tubulin associated (Botling et al. 1994 ). The H69AR. selected for doxorubicin resistance. expresses a multidruc-resistant (MDR phenotype proposed to be mediated by a multidrug resistanceassociated protein (MRP Mirski et al. 1987 : Cole et al. 1992 ). The CENIVM-1. selected for teniposide resistance. expresses an atypical MDR. which is proposed to be topoisomerase LI (topoll) associated (Danks et al. 1987 (Danks et al. . 1988 . The exact mechanism of resistance for the primary resistant ACHN cell line is not know-n and may be multifactorial (Nv-gren and Larsson. 1990 ).
The cell lines w ere grow-n in complete culture medium described belowx at 37^C in humidified atmosphere containing 5%' carbon dioxide. The 8226/Dox, vk-as treated once a month w-ith doxorubicin at 0.24 igc ml-' and the 8226/LR-5 at each change of medium w-ith Mel at 1.53 .gg ml-. The U-937-Vcr was continuously cultured in the presence of 10 ng ml-' vincristine and the H69AR >-as alternately fed w-ith drug-free medium and medium containincg 0.46 zg ml-' doxorubicin. The CEMI/VM-1 cell line was cultured in drug-free medium without anv loss of resistance for a period of 6-8 months. The resistance patterns of the cell lines were routinely confirmed in control experiments.
Patient samples
A total of 49 patient tumour samples from the different dia2nostic group w-as used to determine the actixitx of P2. MIel. and. for comparison. fix-e other cy totoxic drugs w-ere chosen to represent different mechanistic classes. Hoxxever. because of a limited number of cells. all drugs could not be tested in all samples.
Tw-entv-eiaht solid and 21 haematological tumours w-ere used to determine the dose-response relationship for P2 and Mel. The diagnostic groups of oriain w-ere: acute lyvmphocytic leukaemia (seven ) . acute my elocy tic leukaemia (eight). chronic lymphocytic leukaemia (four). myeloma (twxo) . carcinoma of the bladder (one). breast cancer (four). non-small-cell lung cancer (six). oxarian carcinoma (eight). phaeochromocytomra (one) . sarcoma )tu-o). carcinoma of the thy roid ( one). mesothelioma ( one). unknow-n primarx (one) . gastric cancer (one). cardiac carcinoma (one). neuroblastoma ( one ). Tumour tissue from solid tumour samples was minced into small pieces and tumour cells w-ere then isolated by collagenase dispersion followed by Percoll (Kabi-Pharmacia) densit-v aradient centrifuciation . Cell xiabilitv wxas determined by the trypan blue exclusion test and the proportion of tumour cells in the preparation >-as judged by inspection of Iax -Grrinxx-ald-Ciemsa-stained Table 1 Chemical composition of peptichemio oligopeptides were stored frozen at -70°C for up to 2 months until further use.
Under these conditions. no apparent change in drug activity was observed ).
The fluorometric microculture cytotoxicity assay procedure The fluorometfic microculture cytotoxicity assay (FMCA) is based on measurement of fluorescence generated from hydrolysis of FDA to fluorescein by cells with intact plasma membranes and has been described in detail previously well of FDA dissolved in PBS (10 jg ml-') was added. The plates were incubated for 45 min and the generated fluorescence (excitation 480 nm) from each well was measured at 538 nm in a 96well scanning fluorometer (Fluoroscan II. Labsystems Oy, Helsinki. Finland). The fluorescence is proportional to the number of intact cells in the well.
To evaluate the schedule dependency of drug activity. CCRF-CEM cells and ACHN cells were used and were exposed to the drug for 2. 4 or 72 h followed by washing with PBS, addition of new culture medium and analysis at 72 h. Stability of P2 and Mel under assay conditions was investigated by a bioassay. Plates prepared with Mel and P2 were preincubated with 100 Rl medium per well for different time periods. ranging from 0 to 72 h. at 37°C before cell suspension (U-937-GTB) was added. The activity of the drugs after different preincubation times was evaluated by comparing the SI values obtained after a further 72 h incubation with FMCA. as described above.
Quality control
Quality criteria for a successful analysis included a fluorescence signal in the control wells of more than five times mean blank value. a mean coefficient of variation (CV) in the control wells of less than 30% and more than 70% tumor cells in the cell preparation before incubation.
Quantification of FMCA results
Cell survival is presented as survival index (SI). defined as the fluorescence in experimental wells in per cent of that in control wells. with blank values subtracted. The IC., was defined as the concentration giving a SI of 50%.
For both cell lines and primary cultures. the ICsos were evaluated for each individual cell line and drug with custom-made computer software . A delta value was calculated as the logarithm of the IC5O of the individual cell line minus the mean of all ten log IC<os (Fridborg et al. 1996) . The resistance factors (RFs) in each subline were defined as the IC., of the resistant subline divided by the IC., of its sensitive parental cell line. P2 is more potent than the other PTC oligopeptides P2 was the most active m-L-SL oligopeptide. which showed a slightly lower mean IC5, (2.6 jg ml-') compared with Mel (3.9 jg ml-') and m-L-SL (4.1 jg ml-'). However, on a molar basis. the IC5, value for P2 was 3.3 times lower than m-L-SL. P1 showed an IC5o of 4.1 jg ml-' whereas the remaining m-L-SL oligopeptides had IC_ s between 5.8 and 9.1 (Table 2) . P2 was the only oligopeptide producing a SI below 50% in all the tested cell lines (Table 2 ).
P2 appears not to be affected by GSH-associated resistance Although. the overall activity profile resembled that of Mel. P2 appeared not to be affected by GSH-associated resistance as determined by the low resistance factor obtained using the LR5-parental IC< ratio (RF 1.05. Table 3 ). Mel and m-L-SL, on the other hand.
showed RFs of 3.1 and 3.8 respectively. P2 also appeared less sensitive to MRP-associated resistance than Mel and m-L-SL with RFs of 1.55. 4.0 and 4.17 respectively (Table 3) . Neither of the drugs was affected by the remaining resistance mechanisms. (Figure 4 ). was the correlation between P2 and Mel relatively high, indicating a similar mode of action. However, crossresistance to standard drugs determined using the haematological samples was generally low (0.14-0.43. Table 5 ). The correlation with doxorubicin. etoposide and cisplatin was much lower for P2 than Mel. whereas the correlations with cytarabine and vincristine were of similar magnitude (Table 5) P2 shows a similar in vitro therapeutic index to Mel in low-prolifeaing cell systems P2 also showed lower IC 0s than Mel in PBMCs with median values of 0.27 and 4.0 respectively (n = 5). However. when compared with median IC-, values of malignant CLL samples. 0.07 and 1.4 gg ml-' respectively (n = 5) the in vitro therapeutic index (IC_, PBMCs/IC_0 CLL) was 3.9 for P2 and 2.8 for Mel (Table 6) .
DISCUSSION
Mel and m-L-SL are closely related aromatic nitrogen mustard derivatives. The two molecules differ only in the position of the di-(2-chloroethyl) amino-group, which is in the para position in Mel and in the meta position in m-L-SL. By conjugation of additional amino acids to the carboxyl and amino groups of m-L-SL. a complex consisting of six different peptides has been developed. This mixture of peptides. PTC. has shown clinical activity in several human malignancies (Hug et al, 1980; Paccagnella et al. 1986; Zaniboni et al, 1988) . In previous investigations with the human melanoma cell line RPMI 8322. PTC as well as some of its individual peptides were more effective than Mel and m-L-SL (Lewensohn et al, 1991a : Hansson et al. 1991 . Myeloma cells isolated from bone marrow of patients with primary myelomas were more sensitive to PTC than to Mel (Paccagnella et al, 1985) .
In the human melanoma cell line RPMI 8322, used in the abovementioned investigation, we found that one of the peptides in PTC.
, showed a higher toxicity than free m-L-SL as measured by the clonogenic assay (Hansson et al, 1991) .
In the present study we show that P2 was the most active component of PTC when tested in a panel of human tumour cell lines. Moreover, P2 was also more active than Mel and m-L-SL against several of the cell lines. Correlation analysis of cell line panel activity pattems demonstrated a close relationship between P2 and Mel, suggesting a similar mode of action. However. unlike Mel and m-L-SL, P2 appeared not to be affected by GSH-and MRP-associated resistance to any greater extent. We have previously found, using a clonogenic assay, that buthionine sulphoximine, which depletes GSH, sensitizes a melanoma cell line to Mel but to a lesser extent to P2 (Hansson et al, 1991 (1998) found that this peptide used multiple transport pathways in L1210 cells (Yagi et al. 1988 ). Both the above alternatives are currently being explored.
In whole blood P2 is rapidly degraded to m-L-SL. a fact that may limit the activity of the drug in vivo (Ehrsson et al, 1993) . This finding indicates that peptidase activity probably degrades the P2 compound intracellularly. Degradation of di-, tni-and tetrapeptides has previously been observed in erythrocytes and leucocytes that have high peptidase activity (Stem et al, 1951) . More attempts will be made to characterize exactly the intracellular degradation of P2 and test its efficacy in comparison with m-L-SL in vivo.
In the present study, we used a human cell line panel in combination with a panel of primary tumour cultures from patients for in vitro evaluation of differential drug responses of PTC oligopeptides. In a previous study we showed that the present cell line panel is capable of detecting mechanisms of action of standard drugs in addition to its ability to evaluate sensitivity to drugs to defined types of mechanisms of resistance. Complementary to this, non-clonogenic assays used on fresh primary tumour cultures from patients have been shown to mimic the known clinical activity pattern of standard drugs. We have also previously shown that non-clonogenic cytotoxicity assays such as the FMCA can detect tumour type specific activity retrospectively for a series of standard drugs ) and prospectively for early phase I-H drugs such as vinorelbine. idarubicin. CdA. gemcitabine. taxol and topotecan Csoka et al. 1995 : Nygren et al. 1995 : Fridborg et al. 1996 : Jonsson et al, 1997 . Thus, experience gained so far suggests that these model systems may be valid tools for initial predictions of the activity and potential utility of novel anticancer drugs.
In summary, we have demonstrated high anti-tumour activity of a m-L-SL oligopeptide against cell lines and primary cultures of tumour cells from patients. The drug appears to show retained activity against non-proliferating cell systems, shows a positive therapeutic index and demonstrates low levels of cross-resistance with standard drugs. Formal testing of these in vitro predictions will require in vivo testing in relevant tumour models and these studies are currently under way.
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